Advances in the pharmacological management of non-24-h sleep-wake disorder
- 23 February 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 22 (8), 1039-1049
- https://doi.org/10.1080/14656566.2021.1876665
Abstract
Introduction: Melatonin, a hormone that regulates circadian rhythms and the sleep-wake cycle, is produced mainly during the dark period in the pineal gland and is suppressed by light exposure. Patients with non-24-h sleep-wake disorder (non-24) fail to entrain the master clock with the 24-h light-dark cycle due to the lack of light perception to the suprachiasmatic nucleus typically in totally blind individuals or other organic disorders in sighted individuals, causing a progressive delay in the sleep-wake cycle and periodic insomnia and daytime sleepiness. Areas covered: Herein, the authors review the pharmacological therapies including exogenous melatonin and melatonin receptor agonists for the management of non-24. They introduce a historical report about the effects of melatonin on the phase shift and entrainment for blind individuals with the free-running circadian rhythm. Expert opinion: Orally administered melatonin entrains the endogenous circadian rhythm and improves nighttime sleep and daytime alertness for non-24. Currently, tasimelteon is the only approved medication for non-24 by the US Food and Drug Administration and the European Medicines Agency. Treatments that focus only on sleep problems are insufficient for the treatment of non-24, and aids to entrain the free-running rhythm with the light-dark cycle are needed.Keywords
This publication has 105 references indexed in Scilit:
- Melatonin membrane receptors in peripheral tissues: Distribution and functionsMolecular and Cellular Endocrinology, 2012
- New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonistsNeuropsychiatric Disease and Treatment, 2009
- Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic systemEuropean Psychiatry, 2008
- Melatonin in the skin: synthesis, metabolism and functionsTrends in Endocrinology & Metabolism, 2008
- Circadian rhythm sleep disorders: Characteristics and entrainment pathology in delayed sleep phase and non-24 sleep–wake syndromeSleep Medicine Reviews, 2007
- A clinical approach to circadian rhythm sleep disordersSleep Medicine, 2007
- Potent therapeutic effect of melatonin on aging skin in pinealectomized ratsJournal of Pineal Research, 2005
- Melanopsin-Containing Retinal Ganglion Cells: Architecture, Projections, and Intrinsic PhotosensitivityScience, 2002
- Melatonin Inhibits Proliferation and Melanogenesis in Rodent Melanoma CellsExperimental Cell Research, 1993
- Blind Man Living in Normal Society Has Circadian Rhythms of 24.9 HoursScience, 1977